Frailty-independent undertreatment negative impact on survival in older patients with breast cancer

Authors:

Fernando Osório(*) , Breast Center, São João University Hospital, Faculty of Medicine, University of Porto, Portugal

António S. Barros, Department of Surgery and Physiology, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Portugal

Bárbara Peleteiro, Hospital Epidemiology Center, São João University Hospital, EPIUnit, Institute of Public Health, and Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Portugal

Ana Rita Barradas, Department of Internal Medicine, Egas Moniz Hospital, Lisboa, Portugal

Joana Urbano, Department of Internal Medicine, Alto Minho Hospital, Viana do Castelo, Portugal

José Luís Fougo, Breast Center, São João University Hospital, Faculty of Medicine, University of Porto, Portugal

Adelino Leite-Moreira, Department of Surgery and Physiology, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Portugal

(*) corresponding author
ABSTRACT

Introduction: The management of older patients with breast cancer remains controversial. The difficult assessment of ageing idiosyncrasies and the insufficient evidence of therapeutic guidelines can lead to undertreatment. Our goal was to measure undertreatment and assess its impact on survival.

Materials and methods: Consecutive patients with breast cancer aged 70 years or older were prospectively enrolled in 2014. Three frailty screening tools (G8, fTRST, GFI) and two functional status scales (KPS, ECOG-PS) were applied. Disease characteristics, treatment options and causes of mortality were recorded in a 5-year follow-up. We defined undertreatment and correlated its survival impact with frailty.

Results: A total of 92 patients were included. Median age was 77 (range 70-94) years. The prevalence of frailty was discordant (G8: 41.9%, fTRST: 74.2%, GFI: 32.3%). A low-risk disease was not found (51.2% were N+) probably due to a late diagnosis (76.1% based on self-examination). Thirty-three patients (35.6%) died 15 of them from breast cancer. We found a considerable high proportion (53.3%) of undertreatment, which had a frailty-independent negative impact on 5-year survival (HR=5.1 [95% CI: 2.1-12.5]). Additionally, omission of surgery had a frailty-independent negative impact on overall survival (HR=3.9 [95% CI: 1.9-7.9]).

Conclusion: Breast cancer treatment in older adults ought to be individualized. More important than assessing frailty (not to treat) is essential to be aware of the risk-benefit profile and the patient's well-informed willingness to be treated. The undertreatment in daily practice is frequent and might have, as we report, a negative impact on survival.

Keywords: Breast cancer, older adult, geriatric assessment, undertreatment, survival

Highlights:
The breast cancer treatment in older adults must be individualized
The prevalence of frailty on screening scales is discordant
Half of older adults with breast cancer are undertreated in daily practice
The undertreatment in older patients with breast cancer has a significant negative impact on 5-year survival
The omission of surgery in older patients with breast cancer has a negative impact on 5-year survival
INTRODUCTION

Population extended lifespan is an emerging reality [1,3]. In Portugal, in the last sixty years, the population aged 65 or over almost tripled from 8% in 1961 to 22% in 2019 [2]. In 2050, the over-65 population in the European Union (EU) will reach 28.5%, with women outnumbering men. [3].

The increased longevity of older adults has led to a growing incidence of cancer, a disease associated with ageing. A higher proportion of women will warrant the foreseen rising incidence of breast cancer (BC) reaching a peak in women aged 70-84 years [4-6]. BC is the commonest cancer affecting European women with significant survival improvement in the last decades. The 5-year relative survival is 82% in the EU, 83% in Portugal, and 90% in the USA but with pronounced differences between age groups and significantly worst in older patients (50% in over-75 women) [4-6]. Despite competing non-cancer mortality causes, BC is the cause of death in up to 40% of over-80 women [7].

The best multimodality therapeutic strategy in older patients with BC has always been and will remain controversial [7,10-13]. Chronological age alone should not condition it [7,11,38]. The decision-making at the multidisciplinary meeting (MDM) should be standardized and supported by level 1 evidence and simultaneously individualized after a multidimensional evaluation. Therefore, it is crucial to standardize the widely recommended geriatric assessment strategy in oncology [7,8,11]. Too many and distinct tools described in the literature to assess the functional, nutritional, cognitive status, comorbidities, polymedication, and geriatric syndromes hamper a consensus about the MDM's best daily practice solution for a tailored plan [9,29-34]. Moreover, the well-known underrepresentation of older adults in randomized controlled trials (RCT) evaluating cancer treatments due to the heterogeneity of their vulnerable physiology, confounding comorbidities or drug interactions, and the likely lower adherence to therapy or the competing non-cancer mortality hinder to obtain evidence-based guidelines [13-16]. Women older than 70 were precluded even from the paradigm-changing Veronesi’s Milan trials that validated breast conservative surgery (BCS) [17].

In older women, the myth of BC being biologically less aggressive, the stigma of chronological age and the unknown benefit of several treatments (standard for younger patients) are the main reasons for frequent undertreatment that might affect cancer lethality [11,13,15]. Defining undertreatment in the older patients, especially in the frailty ones, is not consensual. It is often considered when internationally defined therapeutic standards are not followed. Knowing when and how to treat, considering
compliance to the proposed treatment, its potential adverse effects, avoiding undertreatment with impact on survival, and knowing individual patient preferences and precluding unnecessary overtreatment, requires a well-trained clinical communication with the older patient and her caregiver and family [18,30].

This study aimed to evaluate undertreatment and its potential impact on 5-year survival in an older adult population aged 70 or over, with BC treated in 2014 at the Breast Center of São João University Hospital (CM-CHUSJ).
MATERIALS AND METHODS:

Our study enrolled 92 consecutive patients over 70 years with de novo BC from January to December 2014. Data were obtained prospectively during routine medical visits and retrieved from patient's digital records. Patients admitted with locoregional or distant recurrences of a previous BC were excluded. The 5-year follow-up ended on December 31st, 2019.

Sociodemographic characterization and an evaluation of the activities of daily living (ADLs), using the Lawton-Brody scale (scores 0: dependent and 1: autonomous) were registered [19]. We also assessed the psychological context, using the Hospital Anxiety-Depression Scale, focusing our measurement on its depressive component (scores 0-7: healthy, 8-11: borderline and ≥12: psychopathology) [20]. The questionnaires were carried out in person or by telephone. The source of information was the patient in 80% or a family member in 20%. The application time had an average of 7 (range 5-12) minutes.

A geriatric assessment was made in an additional hospital visit before the MDM, by applying three frailty screening tools – Geriatric 8 (G8)(score ≤14: frailty, ≥15: risk absent)[21], Flemish version of the Triage Risk Screening Tool (fTRST)(frailty if ≥ 1 point, risk absent if 0 points)[22] and the Groningen Frailty Indicator (GFI)(4-15 points: frailty, 0-3 points: risk absent)[23], combined with two functional assessment scales, the Karnofsky performance score (KPS, from 10 to 100%)[24] and the Cooperative Oncology Group Performance Status scale (ECOG-PS, from 0 to 4)[25,26]. The evaluation time took, on average, 15 (range 11-18) minutes.

The patient and tumor characteristics, SEER and TNM staging, therapeutic options, and death causes during the follow-up were recorded. Tumors were classified according to the TNM-classification of the UICC, 7th edition 2009. MDM decisions were based on CM-CHUSJ written protocols that follow national and international standards.

In our study, we defined undertreatment 1) when the patient refused the MDM proposal, 2) when, due to intolerance, it was not possible to complete the treatment defined in the MDM, and 3) when a standard treatment was not proposed in the MDM given the advanced chronological age or limiting physiological vulnerability.

Statistical analysis

For continuous variables, normality was assessed by Shapiro-Wilks or Kolmogorov-Smirnov tests and by visual inspection of the data distribution. If normally distributed, the results were summarized by the mean and standard deviation; otherwise, the
median and the interquartile range was used. Student's t-test assessed the differences of the independent variables between the two groups (standard treatment and undertreatment) once normality was demonstrated; otherwise, the Wilcoxon rank-sum test was applied. Absolute (n) and relative (%) frequencies were reported for the categorical variables. The Chi-square test and Fisher's exact test assessed the association between the independent categorical variables and the defined groups. Propensity score matching (PSM) was used to reduce covariates' bias, such as frailty, SEER, and TNM scores on assessing the effect of treatment on survival. Survival analyses were performed using Cox proportional hazards models and the Kaplan-Meier method. All statistical analyses were performed using the survminer (version 0.43.1) and survival (version 2.43.3) packages in R (version 3.5.3) (R Core Team 2017. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).
RESULTS

Our observational study included 92 patients (one male), which represented 26.1% of the new BC cases treated at CM-CHUSJ in 2014. The median age was 77 (range 70-94) years.

Forty-four (47.8%) were widows, and forty-two (45.7%) were married. Most (74.0%) either had no education or attended primary school, and 12.0% had a university degree. Seventy (76.1%) patients agreed to answer sociodemographic, psychological, and ADLs questionnaires: thirty-three patients (47.1%) reported feeling "younger" than they were; sixty-four (91.4%) mentioned having a "taste for life"; half lived with her husband and 15.7% lived alone; most patients (77.1%) assessed themselves as autonomous without any need for support from family members; thirty-two patients (45.7%) were completely independent in their ADLs, and 28.6% had only mild dependence. We assessed the occurrence of falls in the last year, one of the first indicators of frailty. Fifty (71.4%) had not suffered any fall; however, half of them emphasized that they were "afraid of falling". In the psychological assessment, most patients (71.4%) were classified as healthy, and 15.7% were depressed (Appendix A).

Sixty-two (67.4%) patients agreed to undergo a geriatric evaluation. The categorization of frailty on the 3 scales was discordant (G8: 41.9%, fTRST: 74.2%, GFI: 32.3%). We also applied the traditional functional scales, illustrating their higher agreement (ECOG-PS 0: 45.7%, KPS 90-100%: 47.8%) (Appendix B).

Most patients presented with a palpable mass (73.9%) detected by the patient or by a family member during hygiene care. In 2 patients, the diagnosis was made during the study of symptomatic metastatic bone disease. Surveillance imaging exams detected only 23.9%, and of these, only one patient was referred from the mass screening program (Appendix B).

There was a predominance of stage IA (27.2%) and IIA (26.1%) in TNM staging, in contrast to 6.5% in stage 0 and 7.6% in stage IV. Using the SEER summary staging system to classify our invasive tumors leads to an unexpectedly similar distribution between local (48.8%) and regional disease (43.1%). Concerning invasive tumors, the predominant histological subtype was "no special type" (75.6%); the Bloom-Richardson grading was evenly distributed (33.7% were G3, 39.5% G2, and 26.7% G1), and lymphovascular invasion was present in 31.4%. Regarding immunohistochemistry (IHC), 83.0% were ER positive, 71.0% PR positive, and 11 tumors (12.8%) were HER2 positive. Concerning molecular classification, 82.6% had luminal-like tumors, 5.8% were HER2 enriched, and 11.6% were triple-negative (TN). A
more specific subdivision of luminal tumors was not possible as HER2 status was not studied in 18, nor was Ki67 in 16 cases.

Eighteen patients (19.6%) were referred to genetic counseling: the man, 8 women with previous contralateral tumors, 5 with bilateral synchronous tumors, 3 with suggestive family history, and one with previous ovarian cancer. Only one patient was BRCA2 positive.

The MDM decision-making was consensual in 61 patients (66.3%) but controversial and adapted in 31 patients (33.7%), due to frailty in 18 and advanced chronological age in 13. One patient, the only male, refused any kind of treatment. Seventy-four (80.4%) patients were submitted to surgery (55.4% underwent BCS) and eighteen (19.6%) patients were not operated. Of these, 15 (16.3%) patients underwent primary endocrine therapy (PET): 4 refused surgery and 11 had no physiological conditions. Seven (7.6%) patients underwent neoadjuvant chemotherapy, and 2 of them – with stage IV Luminal B-HER2 positive tumors – were not proposed for surgery afterward. Of the 68 patients with invasive tumors submitted to surgery, only 2 frail patients (aged 90 and 83) with TN tumors were not proposed for adjuvant treatment. The remainder were submitted to various combinations of adjuvant treatment: 55 (80.9%) to endocrine therapy, 46 (67.6%) to radiotherapy, 21 (30.9%) to chemotherapy, and 9 (13.2%) to trastuzumab.

According to our pre-specified definition, 49 patients (53.3%) were undertreated (Appendix C, D). KPS and ECOG-PS showed a significant difference between undertreatment and standard treatment groups. Conversely, the chronological age, the three frailty screening tools applied, and comorbidities were not associated with the treatment outcomes. Regarding the diagnosis and staging (TNM and SEER), we found a significant difference between undertreatment and standard treatment groups. Analyzing by molecular subtypes, no relevant difference was found regarding undertreatment, probably due to its inaccurate classification (Table 1).

Our patients’ overall 5-year survival was 66.1% [95% CI: 57.0%, 76.5%] (Appendix E). Thirty-three (35.9%) patients died; fifteen (45.5%) due to BC, most with M1 bone plus visceral disease (Appendix C). Eighteen (54.5%) died from a non-cancer cause; however, four of these (22.2%) had stable M1 disease. Of the 33 patients who died, 27 (81.8%) were undertreated in contrast to the 52 patients alive without any evidence of oncological disease at the end of the follow-up, in which only 30.8% were undertreated. No significant differences in survival status were found when comparing death from all causes and death from BC (Appendix F). Thus, the vital status was aggregated.
A relevant finding was the undertreatment impact on 5-year survival stratified by the type of cancer treatment (HR=5.1 [95% CI: 2.1-12.5])(Figure 1). Our undertreated patients had an overall 5-year mortality rate of 55.1% (and 24.5% of cancer lethality rate) in contrast to the standard treatment group, in which the overall 5-year mortality rate was only 13.9% and 7.0% of cancer lethality rate. To mitigate the contribution of frailty on the overall survival status, a propensity score matching of patients using frailty scores highlights the worse prognosis for the undertreatment group (HR=9.3 [95% CI: 2.7-32.0])(Figure 2). A subanalysis regarding the omission of surgical treatment showed a significant association with undertreatment well supported by the clear negative impact on survival – held, even after frailty-matching of non-operated patients (Figure 3,4).
DISCUSSION

The definition of geriatric age should consider chronological age, biological age, social role change, or functional capacities. We used (as stated by SIOG, EORTC, or NCCN) the 70 years’ cut-off, but this landmark lacks consensus [3,7,8,11,16,38].

Half of our patients have good self-perceived health. Indeed, the question in the G8 tool[21] – "in comparison with other people of the same age, how does the patient consider her health status" – reported that 51.6% considered their health status to be as good or better than other ones. This figure is in-line with the 49.7% healthy EU population aged 65-74 with good self-perceived health in a recent ageing study [3]. Therefore, we can consider that our patients are resilient: 91.4% like to live, 71.4% have not suffered any fall, 47.1% feel younger than their chronological age, and 45.7% were completely independent in their ADLs and ECOG-PS 0. The ability to translate this resilience into daily practice – the mirror-image of frailty – with a more positive connotation, more than a taxonomic debate, allows us to refocus on a subgroup of fit patients and to provide them a better MDM guidance [28,34].

Contrary to the current (screening-driven) trend in BC diagnosis, we found a late diagnosis mostly clinically based. As in other studies, only 23.9% of patients were diagnosed with periodic surveillance imaging, explaining why only 6.5% of DCIS were observed (instead of the expected 16-18%)[5,41,42]. Given the mentioned generational change, it is time to offer women over 70 years the mass mammography screening since some studies showed a survival benefit for older women with a life expectancy of more than 10 years [40]. A late diagnosis consequence was a more advanced TNM staging (51.2% were N+). Indeed, this is clear through the SEER summary staging applied to our invasive tumors: 48.8% had local disease (instead of the expected 64%) and 43.1% regional disease (more than the estimated 27%)[5]. More evident is our worst 5-year overall survival - excluding the HER2 enriched tumors - comparing to all-ages 2019-2020 ACS statistics (Table 2). Contrary to other studies [13,42], a more favorable tumor biology was not found (33.7% were G3 and 31.4% had lymphovascular invasion), which, on top of an incomplete IHC study (HER2 missing in 20.9% due to an advanced age preconceived intention-not-to-treat) might constrain the MDM decision causing a worse prognosis.

The best BC diagnostic and treatment strategy in older women remains challenging to define [7,10,13,16,27,47]. Likewise, the definition and mainly the clinical impact assessment of BC undertreatment is also elusive as it involves more than one and sequential therapeutic modalities [16,18,27,44,45]. The key question is whether we can tailor the treatment, knowing the physiological reserve, comorbidities,
vulnerabilities, and patient will. The geriatric evaluation performed and the explanation of its goals allowed to create a time-consuming, difficult-to-measure but rewarding open discussion with our patients about their cancer diagnosis and the risk-benefits of their treatments that will provide proper support to MDM therapeutic management [27,33,38]. There are several geriatric tools and strategies recommended in the literature [29-39]. A geriatric comprehensive assessment was not yet carried out by us in 2014. The G8 screening tool - chosen for EORTC trials [16] - consensually emerged as a good predictor of geriatric risk and overall survival [37]. As seen in other studies [31], the categorization of frailty in the three applied screening tools was discordant, and none of them showed an association with undertreatment.

Age is a proven independent risk-factor for non-standard BC treatment [7,10,30,39]. A significant, albeit variable, amount (in some studies well above 50%) of older adults with BC are undertreated [13,44-46]. In our cohort it represented 53.3%. Our study's key answer is whether age-related BC undertreatment is itself a determinant cause of a worst 5-year survival or a consequence of a limiting fragility. Co-morbid illnesses and functional status probably influence more older patients' life expectancy than the BC itself [27]. Age, frailty, and comorbidities are non-modifiable risk-factors that predict overall mortality. On the other hand, tumor biology and TNM stage are modifiable risk factors for cancer lethality. We clearly show a negative impact of BC undertreatment - independent of frailty - on 5-year survival (Figure 1,2). An unfit older patient with a luminal BC and a short life expectancy is adequately treated with PET. Surgery in these patients will offer better local control but probably has no impact on overall survival. Instead, fit older adults must undergo a standard treatment to avoid shortening their life expectancy [30,44]. An unproven survival benefit of the different therapeutic modalities due to ageing idiosyncrasies does not allow an accurate prognosis evaluation in older patients [41-47]. Despite the variability of our cohort [48,49], we show a frailty-independent negative impact of the omission of surgery on 5-year survival (Figure 3,4).

Our study’s main limitations are the small sample size, the incomplete IHC characterization, single-center study, and the lack of a formal assessment of patient-reported outcomes or health-related quality of life. As for strengths, we emphasize being a real-world study with complete clinical data, a resilient cohort with no loss to 5-year follow-up, and all causes of death verified.
CONCLUSION

The BC treatment in older adults must be individualized. An assumed more favourable tumor-biology disease in a heterogeneous age subgroup is currently treated without the support of RCT evidence-based recommendations.

In our study, we did not find a low-risk disease; the BC diagnosis was late (mainly based on self-examination), contributing to worse prognosis (only 6.5% of DCIS, 51.2% of the invasive tumors were N+, 33.7% were G3, and 8.1% M1). The prevalence of frailty in the applied screening tools was discordant (G8: 41.9%, fTRST: 74.2%, GFI: 32.3%), and most of the studied patients showed resilience.

In older women, BC treatment more than assessing the frailty for treatment conditioning; it is essential to know the physiological reserve and the patient’s well-informed willingness to be treated. In older patients, the concept and the clinical impact of undertreatment remain difficult to establish. We found a considerable proportion (53.3%) of undertreatment with a significant negative impact on 5-year survival independent of frailty. Moreover, we show a frailty-independent positive impact of surgical treatment on overall survival.

Time and dedication to an integrated geriatric evaluation and good clinical communication to assess the risk-benefit profile are essential for older adults centered-care and appropriate oncologic decision-making that minimize undertreatment and avoid its potential adverse impact on survival.
DECLARATIONS:

Abbreviations
ACS: American Cancer Society; ADL: activities of daily living; BC: breast cancer; BCS: breast conservative surgery; CI: confidence interval; CM-CHSU: Breast Center of São João University Hospital; DCIS: ductal carcinoma in situ; ECOG-PS: Cooperative Oncology Group Performance Status scale; EORTC: European Organisation for Research and Treatment of Cancer; ER: Estrogen receptor; EU: European Union; fTRST: Flemish version of the Triage Risk Screening Tool; G8: Geriatric 8 screening tool; GFI: Groningen Frailty Indicator; HER2: human epidermal growth factor receptor-2; HR: hazard ratio; IHC: immunohistochemistry; Ki-67: proliferation index marker; KPS: Karnofsky performance score; MDM: multidisciplinary meeting; NCCN: National Comprehensive Cancer Network; PET: primary endocrine therapy; PR: Progesterone receptor; RCT: randomized controlled trials; SEER: Surveillance, Epidemiology, and End Results Program; SIOG: International Society of Geriatric Oncology; TN: triple negative; TNM: Classification of Malignant Tumors; USA: United States of America.

Ethics approval and consent to participate
The study ("Geriatric evaluation in older patients with breast cancer – a clinical pathway validation") was performed in accordance with the ethics international guidelines and approved by the Ethics Committee of São João University Hospital on June 28th 2013 (CES 111-13). Written study information was provided and a written informed consent was obtained from all participants. The study enrolment took place during 2014.

Consent for publication
Not applicable

Availability of data and materials
All relevant data analyzed during this study are included in this published article and additional tables and figures are available as supplementary material. Other data requests can be submitted to the corresponding author.

Competing interests
All authors declare that they have no competing interests.
Funding
This article publication was supported by National Funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).

Authors´ contributions
FO, BP, ASB, JLF and AL-M defined the study design. FO, ARB and JU made the data acquisition. ASB and BP defined the statistical analysis. ASB prepared the figures and tables. FO, BP and ASB wrote the manuscript. All authors reviewed and approved the submitted manuscript. All authors shared the decision to submit the paper for publication.

Acknowledgements
Not applicable

Authors´ information
Fernando Osório and José Luís Fougo from Breast Center, São João University Hospital, Faculty of Medicine, University of Porto, Portugal; António S. Barros and Adelino Leite-Moreira from Department of Surgery and Physiology, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Portugal; Bárbara Peleteiro from Hospital Epidemiology Center, São João University Hospital, EPIUnit, Institute of Public Health, and Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Portugal; Ana Rita Barradas from Department of Internal Medicine, Egas Moniz Hospital, Lisboa, Portugal and Joana Urbano from Department of Internal Medicine, Alto Minho Hospital, Viana do Castelo, Portugal.
BIBLIOGRAPHY

1- Ministério da Saúde (2018), Retrato da Saúde, Portugal. ISBN 978-989-99480-1-3
2- Base de Dados de Portugal Contemporâneo, Fundação Francisco Manuel dos Santos, Portugal. https://www.pordata.pt (accessed 25 October 2020)
3- European Commission - EUROSTAT. Ageing Europe - Looking at the lives of older people in the EU. 2019. Statistical books (https://doi.org/10.2785/811048)
4- Siegel RL, Miller KD, Jemal A. Cancer Statistics 2020. CA Cancer J Clin 2020; 70: 7-30 (https://doi.org/10.3322/caac.21590)
5- American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Am Cancer Soc 2019; 1-44
6- Sant M, Chirlaque Lopez MD, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCare-5 study. Eur J Cancer 2015; 51(15): 2191-205 (https://doi.org/10.1016/j.ejca.2015.07.022)
7- Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIGO) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13(4): e148-60 (https://doi.org/10.1016/s1470-2045(11)70383-7)
8- Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014; 32(24): 2595-603 (https://doi.org/10.1200/jco.2013.54.8347)
9- Sattar S, Alibhai SMH, Wildiers H, Puts MTE. How to implement a geriatric assessment in your clinical practice. Oncologist 2014; 19: 1056-68 (https://doi.org/10.1634/theoncologist.2014-0180)
10- Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older Crit Rev Oncol Hematol 2003; 46(2): 121-6 (https://doi.org/10.1016/S1040-8428(02)00133-6)
11- Hurria A, Wildes T, Blair SL, et al. Senior adult oncology, version 2.2014: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014; 12(1): 82-126 (https://doi.org/10.6004/jnccn.2014.0009)
12- Protière C, Viens P, Rousseau F, Moatti JP. Prescribers’ attitudes toward elderly breast cancer patients. Discrimination or empathy? Crit Rev Oncol Hematol 2010; 75: 138-50 (https://doi.org/10.1016/j.critrevonc.2009.09.007)
13- Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol 2013; 2013: 893104 (https://doi.org/10.1155/2013/893104)
14- Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012; 30(17): 2036-8 (https://doi.org/10.1200/jco.2012.41.6727)
15- Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control 2014; 21(3): 209-14 (https://doi.org/10.1177/107327481402100305)
16- Pallis AG, Fortpied C, Wedding U, et al. EORTC elderly task force position paper: approach to the older cancer patient Eur J Cancer 2010; 46(9): 1502-13 (https://doi.org/10.1016/j.ejca.2010.02.022)
17- Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomized trials on 1973 patients. Eur J Cancer 1995; 31A(10): 1574-9 (https://doi.org/10.1016/0959-8049(95)00271-J)
18- Puts TEM, Tu HA, Tourangeau A, et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol. 2014; 25(3): 564-77 (https://doi.org/10.1093/annonc/mdt433)

19- Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3):179-86 (https://doi.org/10.1093/geront/9.3_Part_1.179)

20- Pais-Ribeiro J, Silva I, Ferreira T, et al. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Heal Med 2007; 12(2): 225-37 (https://doi.org/10.1080/13548500500524088)

21- Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. J Clin Oncol. 2011; 29(15_suppl): 9001 (https://doi.org/10.1200/jco.2011.29.15_suppl.9001)

22- Deschodt M, Wellens N, Braes T, et al. Prediction of functional decline in older hospitalized patients: a comparative multicenter study of three screening tools. Aging Clin Exp Res. 2011; 23(5-6): 421-6 (https://doi.org/10.1007/bf03325237)

23- Slaets JP. Vulnerability in the elderly: frailty. Med Clin North Am. 2006; 90(4): 593-601 (https://doi.org/10.1016/j.mcna.2006.05.008)

24- Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In Evaluation of chemotherapeutic agents. Edited by MacLeod CM. New York: Columbia University Press. 1949; 191-205

25- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649-55 (https://doi.org/10.1097/00000421-198212000-00014)

26- Tew WP. An assessment of three Memorial Sloan Kettering pioneers: Karnofsky, Holland & Hurria. J Geriatr Oncol. 2020; 11(2):162-3 (https://doi.org/10.1016/j.jgo.2019.07.001)

27- Tahir M, Robinson T, Stotter A. How not to neglect the care of elderly breast cancer patients? The Breast 2011; 20 (4): 293-6 (https://doi.org/10.1016/j.breast.2011.03.003)

28- Witham MD, Sayer AA. Biological resilience in older people: a step beyond frailty? Eur Ger Med 2015; 6: 101-2 (https://doi.org/10.1016/j.eurger.2014.12.008)

29- Hurria A, Gupta S, Zauderer M, et al. Developing a Cancer-Specific Geriatric Assessment (CARG) A Feasibility Study. Cancer 2005; 104(9): 1998-2005 (https://doi.org/10.1002/cncr.21422)

30- Audisio R. No standard is set for older women with breast cancer. Eur J Surg Oncol 2015; 41: 607-9 (https://doi.org/10.1016/j.ejso.2015.01.033)

31- Montroni I, Rostoft S, Spinelli A, et al. GOSAFE - Geriatric oncology surgical assessment and functional recovery after surgery: early analysis on 977 patients J Geriatr Oncol 2020; 11(2): 244-55 (https://doi.org/10.1016/j.jgo.2019.06.017)

32- Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 2015; 26(2): 288-300 (https://doi.org/10.1093/annonc/mdu210)

33- Hamaker ME, Wildes TM, Rostoft S. Time to stop saying geriatric assessment is too time consuming. J Clin Oncol 2017; 35(25): 2871-4 (https://doi.org/10.1200/jco.2017.72.8170)

34- Williams GR, Kenzik KM, Parman M et al. Integrating geriatric assessment into routine gastrointestinal consultation: The Cancer and Aging Resilience Evaluation (CARE) J Geriat Oncol 2020; 11(2): 270-3 (https://doi.org/10.1016/j.jgo.2019.04.008)
35- Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014; 32(1):19-26 (https://doi.org/10.1200/jco.2013.51.1345)

36- Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak. 2013; 13: 72-8 (https://doi.org/10.1186/1472-6947-13-72)

37- van Walree IC, Scheepers E, van Huis-Tanja L, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriat Oncol 2019; 10 (6): 847-58 (https://doi.org/10.1016/j.jgo.2019.04.016)

38- Shahrokni A, Alexander K. The age of talking about age alone is over. Ann Surg Oncol. 2019; 26(1): 12-4 (https://doi.org/10.1245/s10434-018-6983-7)

39- Soto-Perez-de-Celis E, Li D, Yuan Y, et al. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol 2018; 19 (6): e305-e316 (https://doi.org/10.1016/s1470-2045(18)30348-6)

40- Walter LC, Schonberg MA. Screening mammography in older women: a review. JAMA 2014; 311(13): 1336-47 (https://doi.org/10.1001/jama.2014.2834)

41- Eaker S, Dickman PW, Bergkvist L, Holmberg L. Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med. 2006; 3: 321-8 (https://doi.org/10.1371/journal.pmed.0030025)

42- Bastiaannet E, Liefers GJ, de Craen AJM, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 2010; 124(3): 801-7 (https://doi.org/10.1007/s10549-010-0898-8)

43- Freedman RA, Keating NL, Lin NU, et al. Breast cancer-specific survival by age: worse outcomes for the oldest patients. Cancer 2018; 124(10): 2184-91 (https://doi.org/10.1002/cncr.31308)

44- Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 2003; 21(19): 3580-7 (https://doi.org/10.1200/jco.2003.02.046)

45- Owusu C, Lash TL, Silliman RA. Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat. 2007; 102(2): 227-36 (https://doi.org/10.1007/s10549-006-9321-x)

46- Hancke K, Denkinger MD, Konig J, et al. Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol. 2010; 21(4): 748-53 (https://doi.org/10.1093/annonc/mdp364)

47- Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013; 31(19): 2382-7 (https://doi.org/10.1200/JCO.2012.45.2615)

48- de Glas NA, Jonker JM, Bastiaannet E et al. Impact of omission of surgery on survival of older patients with breast cancer. Br J Surg 2014; 101(11):1397-404 (https://doi.org/10.1002/bjs.9616)

49- Nayyar A, Strassle PD, Iles K, et al. Survival outcomes of early-stage hormone receptor-positive breast cancer in elderly women. Ann Surg Oncol. 2020; 27(12): 4853-60 (https://doi.org/10.1245/s10434-020-0945-1)
| Characteristic                      | Overall, N = 92 | N Standard treatment, N = 43 | Under treatment, N = 49 | p-value |
|------------------------------------|-----------------|------------------------------|--------------------------|---------|
| 5Y Follow-up status                |                 |                              |                          | < 0.001 |
| Alive                              | 59 (64%)        | 37 (86%)                     | 22 (45%)                 |         |
| Dead                               | 33 (36%)        | 6 (14%)                      | 27 (55%)                 |         |
| Age **a**                          | 77 (73, 83)     | 76 (72, 80)                  | 78 (74, 85)              | 0.056   |
| Diagnosis                          |                 |                              |                          |         |
| Imaging                            | 16 (37%)        | 5 (10%)                      |                          |         |
| Mass screening                     | 0 (0%)          | 1 (2.0%)                     |                          |         |
| Self-examination                   | 27 (63%)        | 41 (84%)                     |                          |         |
| Symptomatic **M1** disease         | 0 (0%)          | 2 (4.1%)                     |                          |         |
| KPS **a**                          |                 |                              |                          | < 0.001 |
| 90 – 100                           | 44 (48%)        | 30 (70%)                     | 14 (29%)                 |         |
| 70 – 80                            | 19 (21%)        | 9 (21%)                      | 10 (20%)                 |         |
| 50 – 60                            | 23 (25%)        | 4 (9.3%)                     | 19 (39%)                 |         |
| 30 – 40                            | 6 (6.5%)        | 0 (0%)                       | 6 (12%)                  |         |
| ECOG-PS                            |                 |                              |                          | 0.044   |
| 0                                  | 42 (46%)        | 27 (63%)                     | 15 (31%)                 |         |
| 1                                  | 27 (29%)        | 12 (28%)                     | 15 (31%)                 |         |
| 2                                  | 11 (12%)        | 3 (7.0%)                     | 8 (16%)                  |         |
| 3                                  | 11 (12%)        | 1 (2.3%)                     | 10 (20%)                 |         |
| 4                                  | 1 (1.1%)        | 0 (0%)                       | 1 (2.0%)                 |         |
| G8                                 | 36 (58%)        | 23 (72%)                     | 13 (43%)                 | 0.9     |
| Fit                                | 26 (42%)        | 9 (28%)                      | 17 (57%)                 |         |
| Frail                              | 16 (26%)        | 9 (28%)                      | 7 (23%)                  |         |
| ITRST                              | 46 (74%)        | 23 (72%)                     | 23 (77%)                 | 0.9     |
| Fit                                | 42 (68%)        | 25 (78%)                     | 17 (57%)                 |         |
| Frail                              | 20 (32%)        | 7 (22%)                      | 13 (43%)                 | 0.12    |
| Comorbidities                      |                 |                              |                          | 0.2     |
| 1                                  | 11 (12%)        | 6 (14%)                      | 5 (10%)                  |         |
| 2                                  | 21 (23%)        | 13 (30%)                     | 8 (16%)                  |         |
| 3                                  | 25 (27%)        | 12 (28%)                     | 13 (27%)                 |         |
| 4+                                 | 35 (38%)        | 12 (28%)                     | 23 (47%)                 |         |
| Bloom and Richardson grading       |                 |                              |                          | 0.012   |
| Grade 1                            | 23 (27%)        | 15 (41%)                     | 8 (16%)                  |         |
| Grade 2                            | 34 (40%)        | 15 (41%)                     | 19 (39%)                 |         |
| Grade 3                            | 29 (34%)        | 7 (19%)                      | 22 (45%)                 |         |
| SEER Summary Stage system          |                 |                              |                          | < 0.001 |
| In situ                            | 6 (6.5%)        | 6 (14%)                      | 0 (0%)                   |         |
| Local stage                        | 42 (46%)        | 24 (56%)                     | 18 (37%)                 |         |
| Regional stage                     | 37 (40%)        | 13 (30%)                     | 24 (49%)                 |         |
| Distant stage                      | 7 (7.6%)        | 0 (0%)                       | 7 (14%)                  |         |
| TNM stage                          |                 |                              |                          | < 0.001 |
| Stage 0                            | 6 (6.5%)        | 6 (14%)                      | 0 (0%)                   |         |
| Stage 1                            | 29 (32%)        | 20 (47%)                     | 9 (18%)                  |         |
| Stage    | 33 (36%) | 14 (33%) | 19 (39%) |
|----------|----------|----------|----------|
| Stage III| 17 (18%) | 17 (18%) | 3 (7.0%) |
| Stage IV | 7 (7.6%) | 0 (0%)   | 7 (14%)  |
| Molecular-like classification | 86 | 0.7 |
| Luminal | 47 (55%) | 23 (62%) | 24 (49%) |
| Luminal_HER2_missing | 18 (21%) | 7 (19%) | 11 (22%) |
| Luminal_HER2_positive | 6 (7.0%) | 1 (2.7%) | 5 (10%) |
| HER2-enriched | 5 (5.8%) | 2 (5.4%) | 3 (6.1%) |
| Triple Negative | 10 (12%) | 4 (11%) | 6 (12%) |
| Surgery | 92 | < 0.001 |
| No | 18 (20%) | 0 (0%) | 18 (37%) |
| Yes | 74 (80%) | 43 (100%) | 31 (63%) |

1Statistics presented: n (%); median (IQR)

2Statistical tests performed chi-square test of independence; Wilcoxon rank-sum test; Fisher’s exact test
Table 2. Comparison of our data with all ages ACS BC Facts & Figures 2019-2020

|                      | n (%) | ACS %  | 5Y-survival | ACS 5Y-survival |
|----------------------|-------|--------|-------------|-----------------|
| Local disease        | 42 (48.8%) | 64%   | 76.2%       | 99%             |
| Regional disease     | 37 (43.1%) | 27%   | 56.8%       | 86%             |
| Distant disease      | 7 (8.1%) | 6%     | 14.3%       | 27%             |
| RH+ HER2-            | 47 (54.6%) | 73%   | 63.8%       | 92%             |
| RH+ HER2 missing     | 18 (25.4%) | -     | 50.0%       | -               |
| RH+ HER2+            | 6 (7.0%) | 11%    | 83.3%       | 89%             |
| RH- HER2-            | 10 (11.6%) | 12%   | 50.0%       | 77%             |
| RH- HER2+            | 5 (5.8%) | 4%     | 100%        | 83%             |
Figure 1. Kaplan Meier survival curve. HR for undertreatment [95% CI] = 5.1 [2.1 – 12.5]
Figure 2. Kaplan Meier survival curve (matched for frailty). HR for undertreatment [95% CI] = 9.3 [2.7 – 32.0].
Figure 3. Kaplan Meier survival curve. HR for omission of surgery [95% CI] = 3.9 [1.9 – 7.9]
Figure 4. Kaplan Meier survival curve (matched for frailty). HR for omission of surgery [95% CI] = 8.2 [3.3 - 20.1]